KINETIC-TECHNOLOGIES
15.11.2022 07:01:41 CET | Business Wire | Press release
Power management and video/audio interface IC leader Kinetic Technologies announced two new milestone products that can increase the Power Delivery capability of USB Type-C ports to 140W, removing the barrier to expanding the range of electronic products charged via USB. The KTS1898 is dedicated to switching and protecting VBUS power, while the KTU1128 is dedicated to switching and protecting the CC1/2 and SBU1/2 lines.
The KTS1898 is a low-resistance, 5A load switch with soft-start, overvoltage, “ideal diode” reverse-current, short-circuit, over-current, over-temperature and ESD protection plus integrated surge protection of ±100V, designed to isolate and protect downstream components from abnormal VBUS voltage and current conditions. The fast reverse current protection (ideal diode) allows multiple power paths to be connected to VBUS OUT without interference.
The KTU1128 companion IC is a Thunderbolt compatible, Type-C USB data line protection and switch IC, providing low-resistance, ultra-fast OVP, and surge protection for the CC and SBU lines. Maintaining pin-to-pin compatibility with existing products, the KTU1128 increases the operating tolerance on CC and SBU lines to 32V for short-to-VBUS protection and reduces the quiescent current.
“The KTS1898 and KTU1128 are industry leading devices that allow designers to implement USB Type-C PD3.1 Extended Power Range (EPR) up to 140W and effectively address safety at the same time,” says Erik Ogren, Kinetic Technologies Senior Director of Marketing. “With the ability to withstand up to +35V on VBUS, the KTS1898 delivers the margin our customers require to build 28V systems that are designed to be safe and reliable, while the super low-resistance 25mΩ MOSFET keeps heat to a minimum, which is essential when operating at such high-power levels. The KTU1128 features the same built-in robust protection and together extends Kinetic’s lead in this application.”
KTS1898 and KTU1128 samples are available now with production starting in first quarter 2023. Visit Kinetic Technologies for further information.
Key Product Highlights:
KTS1898 – 28V VBUS Protection
-
3V to 32V Operating Voltage Range
- 35V Abs Max. Rating at IN & OUT
-
5A Continuous Current Rating
- 10A peak
- Supports 140W USB Power Delivery 3.1 (EPR)
- “Ideal Diode” Reverse-current protection with 15µs fast recovery
- Full Protection: OVP, SCP, OCP, OTP & RCP
- IEC61000-4-5 Surge Protection ±100V
- IEC61000-4-2 ESD Protection ±15kV Air, ±8kV Contact
KTU1128 – 28V CC/SBU Protection
-
2.5V to 5.5V Operating Voltage Range
- 32V DC Tolerance on CC1/2, SBU1/2
- Thunderbolt Compatible
- Fast 70ns OVP response time
- IEC61000-4-5 Surge Protection ±40V/±30V CC/SBU
- IEC61000-4-2 ESD Protection ±15kV Air, ±8kV Contact
About Kinetic Technologies
Kinetic Technologies is a global designer, developer, and provider of proprietary and innovative high-performance analog and mixed-signal semiconductor products for a wide variety of markets. Kinetic’s products help its customers efficiently regulate power, intelligently protect their devices from harmful voltage and current spikes, and deliver high-bandwidth, low-latency, and secured connectivity for video, display, and general-purpose applications.
For more information, please visit http://www.kinet-ic.com/.
*Kinetic Technologies’ logo is a trademark of Kinetic Technologies. All other brand and product names appearing in this document are the property of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221113005095/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press release
Intranasal pertussis vaccine candidate BPZE1 demonstrates robust nasal mucosal and systemic immune responses with a favorable safety profile in children ages 6 through 17 yearsFirst pediatric clinical trial builds on 5 prior adult BPZE1 clinical studiesDemonstrates safety and immunogenicity of BPZE1 in acellular pertussis vaccine primed individualsNo interference observed when BPZE1 co-administered with diphtheria and tetanus antigens ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The stu
NIQ Brings New AI and Automation Capabilities to Retail Space Planning and Merchandising2.10.2026 12:45:00 CEST | Press release
New AI and automation capabilities help retailers close execution gaps and scale merchandising decisions across every store. NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced new AI and automation capabilities for NIQ Spaceman®, its retail space planning and merchandising platform trusted by more than 600 retailers across 65+ countries. The enhancements help retailers create store-specific planograms up to 50 times faster, identify execution and compliance gaps, and scale merchandising decisions across their store networks through expanded cloud-based access. "Retailers are under increasing pressure to localize assortments, execute consistently across stores, and respond more quickly to changing shopper behavior," said Natalie Williams, SVP, Product at NIQ. "These enhancements help simplify that process by embedding agentic AI directly into merchandising workflows and automating traditionally manual planning tasks. That means teams can spend less time buil
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2.10.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior leader were granted on September 30, 2026 and consisted of options to purchase an aggregate of 121,800 shares and restricted share units covering an aggregate of 58,000 shares. The options have an exercise price per share equal to $12.44. The equity awards to the ten newly hired non-executive employees were granted on October 1, 2026 and consisted of options to purchase an aggregate of 97,100 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 46,200 shares. These options have an exercise price per share equal to $11.95, the closing price of the Company’s American De
Global Health Leaders to Convene at Abu Dhabi Future Health Summit 20262.10.2026 12:24:00 CEST | Press release
Abu Dhabi Future Health Summit will convene leaders across healthcare, science, technology, policy, and investment from 20-22October at ADNEC Centre Abu DhabiUnder the 2026 theme ‘To Sense is to Predict’, the Future Health Summit will examine how greater health insight can enable earlier intervention and better outcomesAstraZeneca CEO Sir Pascal Soriot, Isomorphic Labs President Mr. Max Jaderberg, Amref Health Africa Group CEO Dr. Githinji Gitahi, and Health Ministers from Kosovo, Montenegro, Serbia and Colombia are among more than 130 Forum speakers, with participation expected from 100 countries Global leaders across healthcare, science, technology, policy, and investment will convene at the Abu Dhabi Future Health Summit from 20 to 22 October 2026 to examine how health systems can better anticipate risk and enable earlier intervention as advances in AI, genomics, diagnostics, and health data create new possibilities for understanding health risks earlier. This press release features
Venture Global and ConocoPhillips Announce 20-Year LNG Sales and Purchase Agreement1.10.2026 22:30:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) and ConocoPhillips (NYSE: COP) announced a new, long-term Sales and Purchase Agreement (SPA) for liquefied natural gas (LNG). Under the SPA, ConocoPhillips will buy 1.0 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030. "Venture Global is proud to welcome ConocoPhillips, one of the world's leading energy companies, as a long-term partner," said Venture Global CEO Mike Sabel. "This agreement reflects continued market confidence in our proven ability to deliver reliable, low-cost U.S. LNG quickly and at scale. We look forward to supporting ConocoPhillips' growing global LNG portfolio for decades to come." About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom